Once Weekly D-cycloserine for Schizophrenia

• Status: Withdrawn
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 4, & 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 weeks in adult outpatients with schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Cycloserine

Criteria

Inclusion Criteria:

1. Male or female

2. Age 18-65 years

3. Diagnosis of schizophrenia or schizoaffective disorder, depressed type

4. Stable dose of antipsychotic for at least 4 weeks.

5. Able to provide informed consent

6. Able to complete a cognitive battery

Exclusion Criteria:

1. Current treatment with clozapine

2. Dementia

3. Seizure disorder

4. Unstable medical illness

5. Active substance abuse

6. Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.

7. Severe renal insufficiency (Serum creatinine > 1.5 mg/dL)